San Francisco startup Composition Therapeutics is likewise working on an oral, when-every day GLP-1 drug called GSBR-1290—the drug surpassed Wall Street’s anticipations in June when a mid-stage research confirmed common weight loss of about 6% and it strategies to start out One more mid-phase trial to the tip of this year—that founder and CEO